Investors are ignoring Luye Pharma Group's limited growth ex...

Investors are ignoring Luye Pharma Group's limited growth expectations, paying up for exposure to the stock. However, maintaining these prices may be difficult as this level of revenue growth is likely to weigh down the shares eventually.